at 007

AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM). It reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.

CCI 007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485

KBC-007 is a synthetic branched chain-containing analog of α-galactosylceramide (α-GalCer). It induces IL-4 and IFN-γ secretion by mouse splenocytes when used at a concentration of 0.5 ng/ml and IL-2 secretion by DN32.D3 NKT hybridoma cells co-cultured with CD1d-transfected RBL cells pre-loaded with KBC-007 at a concentration of 8 ng/ml. KBC-007 (1 μg per animal) increases levels of IL-4, but not IFN-γ, to a similar degree as α-GalCer in mouse serum. KBC-007 (0.5 μg per animal) increases the survival rate of mice immunized with the inactivated influenza A virus A/PR/8/34 in a model of influenza infection.

ADT-007 is an orally active and selective pan-RAS inhibitor with potent anticancer activity.ADT-007 blocks GTP activation of RAS and MAPK/AKT signaling by binding to anucleotide RAS.ADT-007 is used in the study of gastrointestinal cancers.

CXF-007 is a highly effective and selective FGFR4 inhibitor, characterized by an IC 50 value of 7 nM, with demonstrated antitumor activity [1].

XY-06-007, a potent and selective bump-and-hole (B&H) PROTAC BRD4 BD1 L94V degrader, exhibits a DC50, 6 h of 10 nM specifically against BRD4 BD1 L94V without degrading off-targets. It also demonstrates favorable pharmacokinetics for in vivo studies [1].

TUS-007, a modified CANDDY (Chemical knockdown with Affinity aNd Degradation DYnamics) molecule originally derived from a proteasome inhibitor, scarcely affects proteasome activity. It is a potent, orally active degrader of KRAS G12D/V, effective in cell-free chemical knockdown of KRAS G12D/V. Furthermore, TUS-007 has been shown to suppress tumor growth [1].

Compound V007-6018 is a pharmaceutical compound used for drug screening.

IMM-H007 is a novel lipid-lowering agent, increasing abca1 protein expression

G007-LK is a selective inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively.

NCC007 is a novel CKIα and CKIδ dual inhibitors by structural modification of N9 and C2 position of longdaysin.

Compound N007-0014 is a useful organic compound for research related to life sciences and the catalog number is T131372.

ELND007 is a Gamma secretase inhibitor.

MPX-007, a potent NMDA inhibitor, inhibits GluN2A-containing NMDA receptors expressed in HEK cells with IC50s of 27 nM.

JHW 007 hydrochloride is a Dopamine uptake inhibitor.

Compound N007-0024 is a useful organic compound for research related to life sciences and the catalog number is T131370.

NK007 is a novel anti-SARS-CoV-2 agent with an EC50 value of 30 nM.

Compound N007-0023 is a useful organic compound for research related to life sciences and the catalog number is T131371.

AqB007 is a selective blocker of the Aquaporin-1 ion channel conductance, thereby slowing cancer cell migration.

TFC-007 is an inhibitor of hematopoietic prostaglandin D synthase.

Mn007 is a strong inhibitor of bovine pancreatic DNase I, with an IC 50 of 45 μM, achieved through molecular aggregation. Additionally, Mn007 inhibits the growth of S. pyogenes in human whole blood [1].

RS-93427-007 is an orally active stable mimetic agent of prostacyclin for the study of mechanisms of atherogenesis.

RS 61756-007 is a selective thromboxane receptor (TP) agonist.

HB007 is a potent degrader of small ubiquitin-related modifier 1 (SUMO1). It mediates the ubiquitination and subsequent degradation of SUMO1, leading to a decrease in tumor growth in vivo. HB007 is a valuable tool for investigating brain, breast, colon, and lung cancers[1][2].

Datopotamab (CDP7657) is a TROP2-targeting antibody that is a naked antibody to Datopotamab deruxtecan and can be used to synthesize active antibody conjugators (Datopotamab deruxtecan).